251 related articles for article (PubMed ID: 25179768)
1. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results.
Atar D; Arheden H; Berdeaux A; Bonnet JL; Carlsson M; Clemmensen P; Cuvier V; Danchin N; Dubois-Randé JL; Engblom H; Erlinge D; Firat H; Halvorsen S; Hansen HS; Hauke W; Heiberg E; Koul S; Larsen AI; Le Corvoisier P; Nordrehaug JE; Paganelli F; Pruss RM; Rousseau H; Schaller S; Sonou G; Tuseth V; Veys J; Vicaut E; Jensen SE
Eur Heart J; 2015 Jan; 36(2):112-9. PubMed ID: 25179768
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the 'MITOCARE' Study: a phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRO40303 for the reduction of reperfusion injury in patients undergoing percutaneous coronary intervention for acute myocardial infarction.
MITOCARE Study Group
Cardiology; 2012; 123(4):201-7. PubMed ID: 23202613
[TBL] [Abstract][Full Text] [Related]
3. Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins.
Butt N; Bache-Mathiesen LK; Nordrehaug JE; Tuseth V; Munk PS; Bonarjee V; Hall TS; Jensen SE; Halvorsen S; Firat H; Atar D; Larsen AI
Cardiology; 2017; 138(2):122-132. PubMed ID: 28651249
[TBL] [Abstract][Full Text] [Related]
4. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.
Crimi G; Pica S; Raineri C; Bramucci E; De Ferrari GM; Klersy C; Ferlini M; Marinoni B; Repetto A; Romeo M; Rosti V; Massa M; Raisaro A; Leonardi S; Rubartelli P; Oltrona Visconti L; Ferrario M
JACC Cardiovasc Interv; 2013 Oct; 6(10):1055-63. PubMed ID: 24156966
[TBL] [Abstract][Full Text] [Related]
5. Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI).
Siddiqi N; Neil C; Bruce M; MacLennan G; Cotton S; Papadopoulou S; Feelisch M; Bunce N; Lim PO; Hildick-Smith D; Horowitz J; Madhani M; Boon N; Dawson D; Kaski JC; Frenneaux M;
Eur Heart J; 2014 May; 35(19):1255-62. PubMed ID: 24639423
[TBL] [Abstract][Full Text] [Related]
6. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.
Ibanez B; Macaya C; Sánchez-Brunete V; Pizarro G; Fernández-Friera L; Mateos A; Fernández-Ortiz A; García-Ruiz JM; García-Álvarez A; Iñiguez A; Jiménez-Borreguero J; López-Romero P; Fernández-Jiménez R; Goicolea J; Ruiz-Mateos B; Bastante T; Arias M; Iglesias-Vázquez JA; Rodriguez MD; Escalera N; Acebal C; Cabrera JA; Valenciano J; Pérez de Prado A; Fernández-Campos MJ; Casado I; García-Rubira JC; García-Prieto J; Sanz-Rosa D; Cuellas C; Hernández-Antolín R; Albarrán A; Fernández-Vázquez F; de la Torre-Hernández JM; Pocock S; Sanz G; Fuster V
Circulation; 2013 Oct; 128(14):1495-503. PubMed ID: 24002794
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty trial.
Dominguez-Rodriguez A; Abreu-Gonzalez P; de la Torre-Hernandez JM; Gonzalez-Gonzalez J; Garcia-Camarero T; Consuegra-Sanchez L; Garcia-Saiz MD; Aldea-Perona A; Virgos-Aller T; Azpeitia A; Reiter RJ;
J Pineal Res; 2017 Jan; 62(1):. PubMed ID: 27736028
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.
Atar D; Petzelbauer P; Schwitter J; Huber K; Rensing B; Kasprzak JD; Butter C; Grip L; Hansen PR; Süselbeck T; Clemmensen PM; Marin-Galiano M; Geudelin B; Buser PT;
J Am Coll Cardiol; 2009 Feb; 53(8):720-9. PubMed ID: 19232907
[TBL] [Abstract][Full Text] [Related]
9. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Lønborg J; Vejlstrup N; Kelbæk H; Bøtker HE; Kim WY; Mathiasen AB; Jørgensen E; Helqvist S; Saunamäki K; Clemmensen P; Holmvang L; Thuesen L; Krusell LR; Jensen JS; Køber L; Treiman M; Holst JJ; Engstrøm T
Eur Heart J; 2012 Jun; 33(12):1491-9. PubMed ID: 21920963
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study.
Jang IK; Pettigrew V; Picard MH; Kowey PR; Demmel V; Zile MR; Tatsuno J; Wackers FJ; Hibberd M
J Thromb Thrombolysis; 2005 Dec; 20(3):147-53. PubMed ID: 16261287
[TBL] [Abstract][Full Text] [Related]
11. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.
Najjar SS; Rao SV; Melloni C; Raman SV; Povsic TJ; Melton L; Barsness GW; Prather K; Heitner JF; Kilaru R; Gruberg L; Hasselblad V; Greenbaum AB; Patel M; Kim RJ; Talan M; Ferrucci L; Longo DL; Lakatta EG; Harrington RA;
JAMA; 2011 May; 305(18):1863-72. PubMed ID: 21558517
[TBL] [Abstract][Full Text] [Related]
12. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Chia S; Senatore F; Raffel OC; Lee H; Wackers FJ; Jang IK
JACC Cardiovasc Interv; 2008 Aug; 1(4):415-23. PubMed ID: 19463339
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial.
Lincoff AM; Roe M; Aylward P; Galla J; Rynkiewicz A; Guetta V; Zelizko M; Kleiman N; White H; McErlean E; Erlinge D; Laine M; Dos Santos Ferreira JM; Goodman S; Mehta S; Atar D; Suryapranata H; Jensen SE; Forster T; Fernandez-Ortiz A; Schoors D; Radke P; Belli G; Brennan D; Bell G; Krucoff M;
Eur Heart J; 2014 Oct; 35(37):2516-23. PubMed ID: 24796339
[TBL] [Abstract][Full Text] [Related]
14. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.
Eitel I; Wöhrle J; Suenkel H; Meissner J; Kerber S; Lauer B; Pauschinger M; Birkemeyer R; Axthelm C; Zimmermann R; Neuhaus P; Brosteanu O; de Waha S; Desch S; Gutberlet M; Schuler G; Thiele H
J Am Coll Cardiol; 2013 Apr; 61(13):1447-54. PubMed ID: 23466078
[TBL] [Abstract][Full Text] [Related]
15. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention.
Roolvink V; Ibáñez B; Ottervanger JP; Pizarro G; van Royen N; Mateos A; Dambrink JE; Escalera N; Lipsic E; Albarran A; Fernández-Ortiz A; Fernández-Avilés F; Goicolea J; Botas J; Remkes W; Hernandez-Jaras V; Kedhi E; Zamorano JL; Navarro F; Alfonso F; García-Lledó A; Alonso J; van Leeuwen M; Nijveldt R; Postma S; Kolkman E; Gosselink M; de Smet B; Rasoul S; Piek JJ; Fuster V; van 't Hof AWJ;
J Am Coll Cardiol; 2016 Jun; 67(23):2705-2715. PubMed ID: 27050189
[TBL] [Abstract][Full Text] [Related]
16. Intra-coronary morphine versus placebo in the treatment of acute ST-segment elevation myocardial infarction: the MIAMI randomized controlled trial.
Le Corvoisier P; Gallet R; Lesault PF; Audureau E; Paul M; Ternacle J; Ghostine S; Champagne S; Arrouasse R; Bitari D; Mouillet G; Dubois-Randé JL; Berdeaux A; Ghaleh B; Deux JF; Teiger E
BMC Cardiovasc Disord; 2018 Oct; 18(1):193. PubMed ID: 30340532
[TBL] [Abstract][Full Text] [Related]
17. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention.
Freixa X; Bellera N; Ortiz-Pérez JT; Jiménez M; Paré C; Bosch X; De Caralt TM; Betriu A; Masotti M
Eur Heart J; 2012 Jan; 33(1):103-12. PubMed ID: 21846677
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
[TBL] [Abstract][Full Text] [Related]
19. Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).
Daaboul Y; Korjian S; Weaver WD; Kloner RA; Giugliano RP; Carr J; Neal BJ; Chi G; Cochet M; Goodell L; Michalak N; Rusowicz-Orazem L; Alkathery T; Allaham H; Routray S; Szlosek D; Jain P; Gibson CM
Am J Cardiol; 2016 Sep; 118(5):625-31. PubMed ID: 27392509
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
Woo JS; Kim W; Ha SJ; Kim JB; Kim SJ; Kim WS; Seon HJ; Kim KS
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2252-60. PubMed ID: 23868944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
